Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.200
+0.120 (11.11%)
At close: Feb 26, 2026, 4:00 PM EST
1.210
+0.010 (0.83%)
Pre-market: Feb 27, 2026, 7:37 AM EST
Heron Therapeutics Revenue
In the year 2025, Heron Therapeutics had annual revenue of $154.90M with 7.36% growth. Heron Therapeutics had revenue of $40.59M in the quarter ending December 31, 2025, a decrease of -0.47%.
Revenue (ttm)
$154.90M
Revenue Growth
+7.36%
P/S Ratio
1.42
Revenue / Employee
$1,269,705
Employees
122
Market Cap
220.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.90M | 10.62M | 7.36% |
| Dec 31, 2024 | 144.29M | 17.24M | 13.57% |
| Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
| Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
| Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
| Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
| Dec 31, 2019 | 145.97M | 68.49M | 88.41% |
| Dec 31, 2018 | 77.47M | 46.71M | 151.81% |
| Dec 31, 2017 | 30.77M | 29.49M | 2,305.55% |
| Dec 31, 2016 | 1.28M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 646.00K | -655.00K | -50.35% |
| Dec 31, 2010 | 1.30M | 40.00K | 3.17% |
| Dec 31, 2009 | 1.26M | 892.00K | 241.73% |
| Dec 31, 2008 | 369.00K | -43.00K | -10.44% |
| Dec 31, 2007 | 412.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | 5.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Editas Medicine | 46.38M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Cartesian Therapeutics | 1.09M |
| SAB Biotherapeutics | 114.70K |
| NeOnc Technologies Holdings | 59.99K |
HRTX News
- 16 hours ago - Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 8 days ago - Heron: Near The Bottom Of A Trading Range Despite Positives - Seeking Alpha
- 9 days ago - Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - GlobeNewsWire
- 6 weeks ago - Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth - GlobeNewsWire
- 3 months ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 4 months ago - Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewsWire